{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T16:49:25Z","timestamp":1755794965711,"version":"3.44.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,8,16]]},"DOI":"10.7759\/cureus.90253","type":"journal-article","created":{"date-parts":[[2025,8,16]],"date-time":"2025-08-16T22:59:11Z","timestamp":1755385151000},"source":"Crossref","is-referenced-by-count":0,"title":["Exploring Human Epidermal Growth Factor Receptor 2 (HER2)-Low Early Breast Cancer in a Moroccan Population: Clinical Characteristics and Survival Outcomes"],"prefix":"10.7759","author":[{"given":"Meryem","family":"Maskrout","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Farah","family":"Boutaagount","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rania","family":"Mokfi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soundous","family":"Bennour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chaymae","family":"Senoussi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Safiya","family":"Mahlaq","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fadoua","family":"Rais","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ghizlane","family":"Rais","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung H","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021, 71:209-49. 10.3322\/caac.21660","journal-title":"CA Cancer J Clin"},{"key":"ref2","unstructured":"World Health Organization. Breast cancer. (2022). https.\/\/www.who.int\/news-room\/fact-sheets\/detail\/breast-cancer."},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21820","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel RL","year":"2024","unstructured":"Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024, 74:12-49. 10.3322\/caac.21820","journal-title":"CA Cancer J Clin"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-88394-6","article-title":"Clinical characteristics, metastasis patterns, and treatment outcomes of HER2-low breast cancer","volume":"15","author":"Lacruz ME","year":"2025","unstructured":"Lacruz ME, Thies S, Schmidt-Pokrzywniak A, et al.. Clinical characteristics, metastasis patterns, and treatment outcomes of HER2-low breast cancer. Sci Rep. 2025, 15:4584. 10.1038\/s41598-025-88394-6","journal-title":"Sci Rep"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1210314","article-title":"HER-2 ultra-low breast cancer: exploring the clinicopathological features and prognosis in a retrospective study","volume":"13","author":"Shi J","year":"2023","unstructured":"Shi J, Zhang L, Geng C. HER-2 ultra-low breast cancer: exploring the clinicopathological features and prognosis in a retrospective study. Front Oncol. 2023, 13:1210314. 10.3389\/fonc.2023.1210314","journal-title":"Front Oncol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.4143\/crt.2023.1138","article-title":"HER2-low breast cancer: now and in the future","volume":"56","author":"Kang S","year":"2024","unstructured":"Kang S, Kim SB. HER2-low breast cancer: now and in the future. Cancer Res Treat. 2024, 56:700-20. 10.4143\/crt.2023.1138","journal-title":"Cancer Res Treat"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2203690","article-title":"Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer","volume":"387","author":"Modi S","year":"2022","unstructured":"Modi S, Jacot W, Yamashita T, et al.. Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer. N Engl J Med. 2022, 387:9-20. 10.1056\/NEJMoa2203690","journal-title":"N Engl J Med"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-023-07079-8","article-title":"Is HER2 ultra-low breast cancer different from HER2 null or HER2 low breast cancer? A study of 1363 patients","volume":"202","author":"Chen Z","year":"2023","unstructured":"Chen Z, Jia H, Zhang H, et al.. Is HER2 ultra-low breast cancer different from HER2 null or HER2 low breast cancer? A study of 1363 patients. Breast Cancer Res Treat. 2023, 202:313-23. 10.1007\/s10549-023-07079-8","journal-title":"Breast Cancer Res Treat"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.02309","article-title":"Estrogen and progesterone receptor testing in breast cancer: ASCO\/CAP guideline update","volume":"38","author":"Allison KH","year":"2020","unstructured":"Allison KH, Hammond ME, Dowsett M, et al.. Estrogen and progesterone receptor testing in breast cancer: ASCO\/CAP guideline update. J Clin Oncol. 2020, 38:1346-66. 10.1200\/JCO.19.02309","journal-title":"J Clin Oncol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.5858\/arpa.2023-0950-SA","article-title":"Human epidermal growth factor receptor 2 testing in breast cancer: ASCO\u2011CAP guideline update","volume":"147","author":"Wolff AC","year":"2023","unstructured":"Wolff AC, Somerfield MR, Dowsett M, et al.. Human epidermal growth factor receptor 2 testing in breast cancer: ASCO\u2011CAP guideline update. Arch Pathol Lab Med. 2023, 147:993-1000. 10.5858\/arpa.2023-0950-SA","journal-title":"Arch Pathol Lab Med"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2022.996434","article-title":"Moving HER2-low breast cancer predictive and prognostic data from clinical trials into the real world","volume":"9","author":"Di Cosimo S","year":"2022","unstructured":"Di Cosimo S, La Rocca E, Ljevar S, et al.. Moving HER2-low breast cancer predictive and prognostic data from clinical trials into the real world. Front Mol Biosci. 2022, 9:996434. 10.3389\/fmolb.2022.996434","journal-title":"Front Mol Biosci"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-020-00208-2","article-title":"Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer","volume":"7","author":"Schettini F","year":"2021","unstructured":"Schettini F, Chic N, Bras\u00f3-Maristany F, et al.. Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer. NPJ Breast Cancer. 2021, 7:1. 10.1038\/s41523-020-00208-2","journal-title":"NPJ Breast Cancer"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.70637","article-title":"Investigating HER2-low in early breast cancer: prognostic implications and age-related prognostic stratification","volume":"14","author":"Chen E","year":"2025","unstructured":"Chen E, Chen C, Chen Y, et al.. Investigating HER2-low in early breast cancer: prognostic implications and age-related prognostic stratification. Cancer Med. 2025, 14:e70637. 10.1002\/cam4.70637","journal-title":"Cancer Med"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-022-01519-x","article-title":"Clinical significance of HER2-low expression in early breast cancer: a nationwide study from the Korean Breast Cancer Society","volume":"24","author":"Won HS","year":"2022","unstructured":"Won HS, Ahn J, Kim Y, et al.. Clinical significance of HER2-low expression in early breast cancer: a nationwide study from the Korean Breast Cancer Society. Breast Cancer Res. 2022, 24:22. 10.1186\/s13058-022-01519-x","journal-title":"Breast Cancer Res"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2023.104571","article-title":"Comprehensive characterization of HER2-low breast cancers: implications in prognosis and treatment","volume":"91","author":"Li Y","year":"2023","unstructured":"Li Y, Tsang JY, Tam F, Loong T, Tse GM. Comprehensive characterization of HER2-low breast cancers: implications in prognosis and treatment. EBioMedicine. 2023, 91:104571. 10.1016\/j.ebiom.2023.104571","journal-title":"EBioMedicine"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-025-01989-9","article-title":"Pathologic response rates in HER2-low versus HER2-zero early breast cancer patients receiving neoadjuvant therapy: a systematic review and meta-analysis","volume":"27","author":"de Moraes FC","year":"2025","unstructured":"de Moraes FC, de Castro Ribeiro CH, Pess\u00f4a FD, et al.. Pathologic response rates in HER2-low versus HER2-zero early breast cancer patients receiving neoadjuvant therapy: a systematic review and meta-analysis. Breast Cancer Res. 2025, 27:39. 10.1186\/s13058-025-01989-9","journal-title":"Breast Cancer Res"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.02488","article-title":"HER2-low breast cancer: pathological and clinical landscape","volume":"38","author":"Tarantino P","year":"2020","unstructured":"Tarantino P, Hamilton E, Tolaney SM, et al.. HER2-low breast cancer: pathological and clinical landscape. J Clin Oncol. 2020, 38:1951-62. 10.1200\/JCO.19.02488","journal-title":"J Clin Oncol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1186\/s12957-024-03382-w","article-title":"Survival outcomes in HER2-low versus HER2-zero breast cancer after neoadjuvant chemotherapy: a meta-analysis","volume":"22","author":"Xia LY","year":"2024","unstructured":"Xia LY, Cao XC, Yu Y. Survival outcomes in HER2-low versus HER2-zero breast cancer after neoadjuvant chemotherapy: a meta-analysis. World J Surg Oncol. 2024, 22:106. 10.1186\/s12957-024-03382-w","journal-title":"World J Surg Oncol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.906011","article-title":"Clinicopathological characteristics and prognosis of HER2\u2011low early\u2011stage breast cancer: a single\u2011institution experience","volume":"12","author":"Xu H","year":"2022","unstructured":"Xu H, Han Y, Wu Y, et al.. Clinicopathological characteristics and prognosis of HER2\u2011low early\u2011stage breast cancer: a single\u2011institution experience. Front Oncol. 2022, 12:906011. 10.3389\/fonc.2022.906011","journal-title":"Front Oncol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.clbc.2024.05.001","article-title":"Comparison of the pathological complete response rate and survival between HER2-low and HER2-zero breast cancer in neoadjuvant chemotherapy setting: a systematic review and meta-analysis","volume":"24","author":"Liu M","year":"2024","unstructured":"Liu M, Xiang Q, Dai F, Yuan Y, Wu Z, Xiang T. Comparison of the pathological complete response rate and survival between HER2-low and HER2-zero breast cancer in neoadjuvant chemotherapy setting: a systematic review and meta-analysis. Clin Breast Cancer. 2024, 24:575-84.e1. 10.1016\/j.clbc.2024.05.001","journal-title":"Clin Breast Cancer"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-025-00737-8","article-title":"Prognostic difference between early breast cancer patients with HER2 low and HER2 zero status","volume":"11","author":"Cha CD","year":"2025","unstructured":"Cha CD, Kim KE, Kim J, et al.. Prognostic difference between early breast cancer patients with HER2 low and HER2 zero status. NPJ Breast Cancer. 2025, 11:31. 10.1038\/s41523-025-00737-8","journal-title":"NPJ Breast Cancer"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.687244","article-title":"The role of Ki67 in evaluating neoadjuvant endocrine therapy of hormone receptor-positive breast cancer","volume":"12","author":"Zhang A","year":"2021","unstructured":"Zhang A, Wang X, Fan C, Mao X. The role of Ki67 in evaluating neoadjuvant endocrine therapy of hormone receptor-positive breast cancer. Front Endocrinol (Lausanne). 2021, 12:687244. 10.3389\/fendo.2021.687244","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2023.101592","article-title":"Prognostic value of HER2-low status in breast cancer: a systematic review and meta-analysis","volume":"8","author":"Molinelli C","year":"2023","unstructured":"Molinelli C, Jacobs F, Agostinetto E, et al.. Prognostic value of HER2-low status in breast cancer: a systematic review and meta-analysis. ESMO Open. 2023, 8:101592. 10.1016\/j.esmoop.2023.101592","journal-title":"ESMO Open"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/390806-exploring-human-epidermal-growth-factor-receptor-2-her2-low-early-breast-cancer-in-a-moroccan-population-clinical-characteristics-and-survival-outcomes","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,16]],"date-time":"2025-08-16T22:59:13Z","timestamp":1755385153000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/390806-exploring-human-epidermal-growth-factor-receptor-2-her2-low-early-breast-cancer-in-a-moroccan-population-clinical-characteristics-and-survival-outcomes"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,16]]},"references-count":23,"URL":"https:\/\/doi.org\/10.7759\/cureus.90253","relation":{},"ISSN":["2168-8184"],"issn-type":[{"type":"print","value":"2168-8184"}],"subject":[],"published":{"date-parts":[[2025,8,16]]}}}